SC Filed 2023-01-17 Event — SEC 0001104659-23-004260 →

BAKER BROS. ADVISORS LP → ACADIA PHARMACEUTICALS INC ACAD

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 16/100 · Filer 90d Win Rate: 0% · Hist. 90d Edge: +0.0%

Filer track record (4 filings): 0% 90d win rate, +0.0% 90d edge
Held by 1 tracked 13F institutional manager
Moderate short days-to-cover (4.6 DTC)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

4 transactions

0 buys · 2 sales · 2 awards/exercises

Issuer Cluster

3 13D/G filings on this issuer

2 other filings besides this one

Filer Track Record

67 filings by this filer

66 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 4.58

9,094,151 shares short · +9.9% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $90.21M

Point72 Asset Mgmt

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-04-07	Kihara James	officer	Sale	1,030	$22.20	$23K
2026-04-07	Schneyer Mark C.	officer	Sale	2,709	$22.20	$60K
2026-04-05	Kihara James	officer	Option exercise	2,010	—	—
2026-04-05	Schneyer Mark C.	officer	Option exercise	5,276	—	—

Other 13D/G Filings on ACADIA PHARMACEUTICALS INC

Filed	Form	Filer	Stake	Shares
2026-08-07	SCHEDULE 13G	STATE STREET CORP	—	—	view →
2023-05-24	SC	BAKER BROS. ADVISORS LP	—	—	view →

Other Filings by BAKER BROS. ADVISORS LP

Filed	Form	Issuer	Stake	Shares
2026-09-30	SCHEDULE 13D/A	Kodiak Sciences Inc.	35.00%	22,049,297	view →
2026-09-16	SCHEDULE 13D/A	BeOne Medicines Ltd.	—	115,457,154	view →
2026-08-11	SCHEDULE 13D/A	Replimune Group, Inc.	11.80%	11,075,336	view →
2026-07-16	SCHEDULE 13D/A	Celcuity Inc.	9.99%	4,877,963	view →
2026-07-16	SCHEDULE 13G	Celcuity Inc.	—	—	view →
2026-06-15	SCHEDULE 13D/A	BeOne Medicines Ltd. BEIGF	8.00%	115,457,154	view →
2026-05-26	SCHEDULE 13D/A	Kiniksa Pharmaceuticals International, plc KNSA	7.00%	3,231,181	view →
2026-05-11	SCHEDULE 13D/A	Incyte Corp INCY	—	30,865,077	view →
2025-06-30	SCHEDULE	Kymera Therapeutics, Inc. KYMR	9.50%	6,666,540	view →
2024-10-08	SC	Kiniksa Pharmaceuticals International, plc KNSA	—	—	view →
2024-06-14	SC	INCYTE CORP INCY	—	—	view →
2023-12-18	SC	Seagen Inc.	—	—	view →
2023-10-10	SC	Neoleukin Therapeutics, Inc. NGNE	—	—	view →
2023-10-05	SC	MADRIGAL PHARMACEUTICALS, INC. MDGL	—	—	view →
2023-07-19	SC	Neoleukin Therapeutics, Inc. NGNE	—	—	view →
2023-05-24	SC	Prelude Therapeutics Inc PRLD	—	—	view →
2023-05-24	SC	ACADIA PHARMACEUTICALS INC ACAD	—	—	view →
2023-05-03	SC	Seagen Inc.	—	—	view →
2023-03-15	SC	INCYTE CORP INCY	—	—	view →
2023-03-13	SC	Seagen Inc.	—	—	view →

Showing 20 of 66

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →